SML3004

NMDAR/TRPM4 interface inhibitor C8 dihydrochloride

≥98% (HPLC)

• Synonim(y): C8 dihydrochloride, Compound 8 dihydrochloride, N1-[(3-Bromophenyl)methyl]-N1-ethyl-1,2-ethanediamine dihydrochloride
• Wzór empiryczny (zapis Hilla): C₁₁H₁₇BrN₂·2HCl
• Numer CAS: 2243506-33-2
• Masa cząsteczkowa: 330.09
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD31668685
• Assay: ≥98% (HPLC)
• Form: powder or solid
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder or solid
• storage condition: desiccated
• color: white to beige
• solubility: H₂O: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: NCCN(CC)CC1=CC=CC(Br)=C1.Cl.Cl
• InChI: 1S/C11H17BrN2.2ClH/c1-2-14(7-6-13)9-10-4-3-5-11(12)8-10;;/h3-5,8H,2,6-7,9,13H2,1H3;2*1H
• InChI key: AQDSZKTVQVSVNC-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

Compound 8 (C8) is a small molecule that directly targets TRPM4 TwinF domain and blocks its interaction with GluN2A/GluN2B (NR2A/NR2B) I4 domain. C8 prevents NMDAR/TRPM4 interaction-dependent excitotoxicity (death protection EC50 = 2.1 μM 24 h post 10-min exposure of primary murine hippocampal neurons to 20 μM NMDA) without affecting, and even enhancing, NMDAR-mediated essential functions. C8 protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell (RGC) loss in mice in vivo (40 mg/kg i.p. at -16h, -3h before, 0h, 3h, 24h after MCAO or 20 nmol NMDA/2.0 μL by intravitreal injection).

TRPM4 TwinF domain-targeting NMDAR/TRPM4 interaction blocker that protects against TRPM4-mediated excitotoxicity in vitro and in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• WGK: WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable